A recent shortage of a drug for attention-deficit/hyperactivity disorder in the U.S. has sparked a round of finger-pointing between Shire PLC and the Drug Enforcement Agency.

Shire blames the shortage of branded and generic versions of its Adderall XR product on DEA limits on the amount of product Shire can manufacture. The Ireland-based company didn't get DEA clearance on boosting supply until December, which has caused "spotty availability" in some regions of the country this year, said Shire spokesman Matt Cabrey.

...